| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d33e45e5cbd64b8b893bd62ee22a85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a715e3cc143ff405ac2730301657d10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b1d8a1e494fa8d2936e9d8a67ca34cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f839a3a56812c5c5eb4a5e66df7f3ce |
| publicationDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020390788-A1 |
| titleOfInvention |
Association of actives for treating prostate cancer |
| abstract |
The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient. The invention also concerns the use of a p38 inhibitor for restoring the sensitivity to androgen-deprivation therapy (ADT) in patients suffering from prostate cancers having acquired a resistance to ADT following a treatment with an inhibitor of the androgen receptor signaling pathway and wherein the prostate tumour cells express the AR-V7 variant androgen receptor protein. |
| priorityDate |
2017-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |